Schcolnik-Cabrera A, Juárez-López D, Duenas-Gonzalez A.
Perspectives on Drug Repurposing. Curr Med Chem. 2020 Aug 31. doi: 10.2174/0929867327666200831141337. Epub ahead of print
2020
Schcolnik-Cabrera A, Chavez-Blanco A, Dominguez-Gomez G, Juarez M, Lai D, Hua S, Tovar AR, Diaz-Chavez J, Duenas-Gonzalez A.
The combination of orlistat, lonidamine and 6-diazo-5-oxo-L-norleucine induces a quiescent energetic phenotype and limits substrate flexibility in colon cancer cells.
Oncol Lett. 2020 Sep;20(3):3053-3060. doi: 10.3892/ol.2020.11838
2020
Juarez M, Schcolnik-Cabrera A, Dominguez-Gomez G, Chavez-Blanco A, Diaz-Chavez J, Duenas-Gonzalez A.
Antitumor effects of ivermectin at clinically feasible concentrations support its clinical development as a repositioned cancer drug.
Cancer Chemother Pharmacol. 2020 Jun;85(6):1153-1163. doi: 10.1007/s00280-020-04041
2020
González-Fierro A, Dueñas-González A (Correspondiente).
Drug repurposing for cancer therapy, easier said than done.
Semin Cancer Biol. 2019 Dec 23. pii: S1044-579X(19)30410-9. doi: 10.1016/j.semcancer.2019.12.012. [Epub ahead of print] Review.
2019
Dominguez-Gomez G, Cortez-Pedroza D, Chavez-Blanco A, Taja-Chayeb L, Hidalgo-Miranda A, Cedro-Tanda A, Beltran-Anaya F, Diaz-Chavez J, Schcolnik-Cabrera A, Gonzalez-Fierro A, Dueñas-Gonzalez A.
Growth inhibition and transcriptional effects of ribavirin in lymphoma
Oncology Reports 42 (3)1248-1256 F.I. 3.041
2019
Alejandro Schcolnik-Cabrera, Guadalupe Dominguez-Gómez, Alma Chávez-Blanco, Marisol Ramírez-Yautentzi, Rocío Morales-Bárcenas, José Chávez-Díaz, Lucía Taja-Chayeb and Alfonso Dueñas-González
A combination of inhibitors of glycolysis glutaminolysis and de novo fatty acid synthesis decrease the expression of chemokines in human colon cancer cells
Oncology Letters 18:6909-6916 F.I. 1.871
2019
Dueñas-Gonzalez, A; Gonzalez-Fierro, A
Pharmacodynamics of current and emerging treatments for cervical cancer
Expert Opinion On Drug Metabolism & Toxicology 15(8):671-682 F.I. 3.487
2019
Hernandez-Vazquez, E; Chavez-Riveros, A; Romo-Perez, A; Ramirez-Apan, MT; Chavez-Blanco, AD; Morales-Barcenas, R; Duenas-Gonzalez, A; Miranda, LD.
Cytotoxic Activity and Structure-Activity Relationship of Triazole-Containing Bis(Aryl Ether)
Macrocycles. Chemmedchem. (2018), 13(12):1193-1209. FI. 3.009
2018
Onate-Ocana, LF; Cortes, V; Castillo-Llanos, R; Terrazas, A; Garcia-Perez, O; Pitalua-Cortes, Q; Ponce, M; Duenas-Gonzalez, A; Candelaria, M.
Metabolic tumor volume changes assessed by interval (18)fluorodeoxyglucose positron emission tomography-computed tomography for the prediction of complete response and survival in patients with diffuse large B-cell lymphoma.
Oncol Lett. (2018), 16(2):1411-1418. FI. 1.664
2018
Dominguez-Gomez, G; Chavez-Blanco, A; Medina-Franco, JL; Saldivar-Gonzalez, F; Flores-Torrontegui, Y; Juarez, M; Diaz-Chavez, J; Gonzalez-Fierro, A; Duenas-Gonzalez, A.
Ivermectin as an inhibitor of cancer stem-like cells.
Mol Med Rep. (2018), 17(2)3397-3403. FI. 1.922
2018
Coronel, J; Cantu, D; Rodriguez-Morales, M; Cetina, L; Gonzalez-Fierro, A; Duenas-Gonzalez, A.
Carboplatin and low-dose paclitaxel. An effective regimen in older and comorbid patients with advanced cervical cancer. A phase II study.
Eur J Gynaecol Oncol. (2018), 39(6)997-100. FI. 0.617
2018
Juarez, M; Schcolnik-Cabrera, A; Duenas-Gonzalez, A.
The multitargeted drug ivermectin: from an antiparasitic agent to a repositioned cancer drug.
Am J Cancer Res. (2018), 8(2):317-331. FI. 3.998
2018
Schcolnik-Cabrera, A; Chavez-Blanco, A; Dominguez-Gomez, G; Taja-Chayeb, L; Morales-Barcenas, R; Trejo-Becerril, C; Perez-Cardenas, E; Gonzalez-Fierro, A; Duenas-Gonzalez, A.
Orlistat as a FASN inhibitor and multitargeted agent for cancer therapy
Expert Opin Investig Drugs. (2018), 27(5)475-489. FI. 3.883
2018
Serralde-Zuniga, A; Castro-Eguiluz, D; Aguilar-Ponce, JL; Pena-Ruiz, AA; Castro-Gutierrez, JV; Rivera-Rivera, S; Aranda-Flores, C; Casique-Perez, V; Alarcon-Barrios, SE; de la Garza-Salazar, J; Sanchez-Lopez, M; Duenas-Gonzalez, A.
Epidemiological Data on the Nutritional Status of Cancer Patients Receiving Treatment with Concomitant Chemoradiotherapy, Radiotherapy or Sequential Chemoradiotherapy to the Abdominopelvic Area.
Rev Invest Clin. (2018), 70(3)117-120. FI. 1.36
2018
Pérez-Cárdenas E, Taja-Chayeb L, Trejo-Becerril C, Chanona-Vilchis J, Chávez-Blanco A, Domínguez-Gómez G, Langley E, García-Carrancá A, Dueñas-González A.
Antimetastatic effect of epigenetic drugs, hydralazine and valproic acid, in Ras-transformed NIH 3T3 cells.
Onco Targets Ther. (2018), 7;11:8823-8833. FI 2.656
2018
Candelaria M, Burgos S, Ponce M, Espinoza R, Dueñas-Gonzalez A.
Encouraging results with the compassionate use of hydralazine/valproate (TRANSKRIP™) as epigenetic treatment for myelodysplastic syndrome (MDS)
Ann Hematol 96(11):1825-1832 DOI: 10.1007/s00277-017-3103-x
2017
Cervantes-Madrid, D; Dominguez-Gomez, G; Gonzalez-Fierro, A; Perez-Cardenas, E; Taja-Chayeb, L; Trejo-Becerril, C; Duenas-Gonzalez, A
Feasibility and antitumor efficacy in vivo, of simultaneously targeting glycolysis, glutaminolysis and fatty acid synthesis using lonidamine, 6-diazo-5-oxo-L-norleucine and orlistat in colon cancer
Oncol Lett. 13(3)1905-1910 DOI: 10.3892/ol.2017.5615
2017
Espinoza-Zamora JR, Labardini-Méndez J, Sosa-Espinoza A, López-González C, Vieyra-García M, Candelaria M, Lozano-Zavaleta V, Toledano-Cuevas DV, Zapata-Canto N, Cervera E, Dueñas-González A.
Efficacy of hydralazine and valproate in cutaneous T-cell lymphoma, a phase II study
Expert Opin Investig Drugs. Apr;26(4):481-487 DOI: 10.1080/13543784.2017.1291630
2017
Martínez-Mesa J, Werutsky G, Michiels S, Pereira Filho CAS, Dueñas-González A, Zarba JJ, Mano M, Villarreal-Garza C, Gómez H, Barrios CH.
Exploring disparities in incidence and mortality rates of breast and gynecologic cancers according to the Human Development Index in the Pan-American region
Public Health.149:81-88 DOI: 10.1016/j.puhe.2017.04.017
2017
Romo-Perez, A; Miranda, LD; Chavez-Blanco, AD; Duenas-Gonzalez, A; Camacho-Corona, MD; Acosta-Huerta, A; Garcia, A.
Mild C(sp(3))-H functionalization of dihydrosanguinarine and dihydrochelerythrine for development of highly cytotoxic derivatives
Eur J Med Chem. 138:1-12 DOI: 10.1016/j.ejmech.2017.06.021
2017
Schcolnik-Cabrera A, Chávez-Blanco A, Domínguez-Gómez G, Dueñas-González A.
Understanding tumor anabolism and patient catabolism in cancer-associated cachexia
Am J Cancer Res. 7(5):1107-1135 DOI: SIN DOI
2017
Cervera, E; Candelaria, M; Lopez-Navarro, O; Labardini, J; Gonzalez-Fierro, A; Taja-Chayeb, L; Cortes, J; Gordillo-Bastidas, D; Duenas-Gonzalez, A
Epigenetic Therapy With Hydralazine and Magnesium Valproate Reverses Imatinib Resistance in Patients With Chronic Myeloid Leukemia
Clin. Lymphoma Myeloma Leuk., 12(3);207-212, FI.1.88
2012
Duenas-Gonzalez, A; Cetina, L; Coronel, J; Cervantes-Madrid, D
Emerging drugs for cervical cancer
Expert Opin Emerg. Drugs, 17(2):203-218, FI.3.207
2012
Taja-Chayeb L, Agúndez JA, Miguez-Muñoz C, Chavez-Blanco A, Dueñas-Gonzalez A.
Arylamine N-acetyltransferase 2 genotypes in a Mexican population
Genet Mol Res., 11(2):2012, FI.1.184
2012
Duenas-Gonzalez, A; Orlando, M; Zhou, Y; Quinlivan, M; Barraclough, H
Efficacy in high burden locally advanced cervical cancer with concurrent gemcitabine and cisplatin chernoradiotherapy plus adjuvant gemcitabine and cisplatin: Prognostic and predictive factors and the impact of disease stage on outcomes from a prospective
Gynecol. Oncol., 126(3):334-340, FI.3.888
2012
Candelaria, M; de la Cruz-Hernandez, E; Taja-Chayeb, L; Perez-Cardenas, E; Trejo-Becerril, C; Gonzalez-Fierro, A; Chavez-Blanco, A; Soto-Reyes, E; Dominguez, G; Trujillo, JE; Diaz-Chavez, J; Duenas-Gonzalez, A
DNA Methylation-Independent Reversion of Gemcitabine Resistance by Hydralazine in Cervical Cancer Cells
PLoS One, 7(3):e29181, FI.4.092
2012
Dueñas-Gonzalez A, Cetina L, Coronel J, Martinez-Banos D.
Pharmacotherapy Options for Locally Advanced and Advanced Cervical Cancer.
Drugs 70(4): 403-432.
2010
Candelaria M, Arias-Bonfill D, Chávez-Blanco A, Chanona J, Cantú D, Pérez C, Dueñas-González A.
Lack in efficacy for imatinib mesylate as second-line treatment of recurrent or metastatic cervical cancer expressing platelet-derived growth factor receptor alpha.
International Journal of Gynecological Cancer 19:1632-1637.
2009
Vidal-Millán S, Taja-Chayeb L, Gutiérrez-Hernández O, Ramírez Ugalde MT, Robles-Vidal C, Bargallo-Rocha E, Mohar-Betancourt A, Dueñas-González A.
Mutational analysis of BRCA1 and BRCA2 genes in Mexican breast cancer patients.
European Journal of Gynaecological Oncology 30:527-530
2009
Singh N, Dueñas-González A, Lyko F, Medina-Franco JL.
Molecular modeling and molecular dynamics studies of hydralazine with human DNA methyltransferase 1.
ChemMedChem 4:792-799.
2009
Candelaria M, de la Cruz-Hernández E, Pérez-Cárdenas E, Trejo-Becerril C, Gutiérrez-Hernández O, Dueñas-González A.
Pharmacogenetics and pharmacoepigenetics of gemcitabine.
Med Oncol. En prensa
2009
Taja-Chayeb L, Vidal-Millan S, Gutierrez-Hernandez O, Trejo-Becerril C, Perez-Cardenas E, Chavez-Blanco A, de la Cruz-Hernandez E, Dueñas-Gonzalez A.
Identification of a novel germ-line mutation in the TP53 gene in a Mexican family with Li-Fraumeni syndrome.
World Journal of Surgical Oncology 17:97
2009
Cetina L, Garcia-Arias A, Candelaria M, Cantú D, Rivera L, Coronel J, Bazan-Perkins B, Flores V, Gonzalez A, Dueñas-González A.
Brachytherapy versus radical hysterectomy after external beam chemoradiation: a non-randomized matched comparison in IB2-IIB cervical cancer patients.
World Journal of Surgical Oncology 7:19
2009
